ProCE Banner Activity

An Expert’s Guide to ASH 2024: Preview of the Top Abstracts

Conference Coverage
Clinical Thought

Experts highlight key studies being presented at the upcoming 2024 ASH Annual Meeting and Exposition. CCO’s Independent Conference Coverage will include timely summaries and practical implications of the latest research and developments in hematology to help you stay at the forefront of advances in cancer care.

Released: December 05, 2024

Expiration: December 04, 2025

Share

Faculty

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation

Disclosure

Primary Author

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jeremy S. Abramson, MD, MMSc: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Celgene, Cellectar, Foresight Diagnostics, Genentech, Gilead, Interius, Roche; researcher: Bristol Myers Squibb, Celgene, Cellectis, Genentech, Merck, Mustang Bio, Regeneron, Seagen, Takeda.

Catherine M. Broome, MD

Professor of Medicine
Director of Cellular Apheresis
Lombardi Cancer Center
MedStar Georgetown University
Washington, DC

Catherine M. Broome, MD: consultant/advisor/speaker: Alexion, Argenx, Sanofi; researcher: Alpine.

Jonathon B. Cohen, MD, MS

Professor, Hematology and Medical Oncology
Winship Cancer Institute
Emory University
Atlanta, Georgia

Jonathon B. Cohen, MD, MS: consultant/advisor/speaker: ADCT, AstraZeneca, BeiGene, Loxo/Lilly; researcher: AstraZeneca, Bristol Myers Squibb/Celgene, Genentech, HutchMed, Loxo/Lilly, Novartis, Takeda.

Corey Cutler, MD, MPH

Director, Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Corey Cutler, MD, MPH: consultant/advisor/speaker: CareDx, Cimeio, CSL Behring, Incyte, OrcaBio, Oxford Immune Algorithmics, Sanofi, Syndax; publicly traded stock/stock options: Cimeio, OrcaBio, Oxford Immune Algorithmics.

Courtney DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
University of Texas MD Anderson Cancer Center
Houston, Texas

Courtney DiNardo, MD, MSCE: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bristol Myers Squibb, Rigel, Servier, Schrodinger.

Rami Komrokji, MD

Vice Chair, Department of Malignant Hematology
Senior Member and Professor of Oncologic Sceinces
H. Lee Moffitt Cancer Center
Tampa, Florida

Rami Komrokji, MD: consultant/advisor/speaker: Bristol Myers Squibb, Daiichi Sankyo, Geron, Jazz, PharmaEssentia, Rigel, Sevier, Sobi, Sumitomo; researcher: Keros.

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Sagar Lonial, MD, FACP: consultant/advisor/speaker: AbbVie, Amgen, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Novartis, Pfizer, Regeneron, Takeda; researcher: Bristol Myers Squibb, Janssen, Novartis, Takeda; other financial or material support: TG Therapeutics.

Noopur Raje, MD

Director, Center for Multiple Myeloma
Rita Kelly Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Caribou, Genentech, Immuneel, Johnson & Johnson, Pfizer, Sanofi.

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M. Stein, MD: consultant/advisor/speaker: Syndax.

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology Clinical Trials Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Co-Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Medical Oncology and Hematology, Department of Internal Medicine
Yale School of Medicine and Yale Comprehensive Cancer Center
New Haven, Connecticut

Amer Zeidan, MBBS, MHS: consultant/advisor/speaker/clinical trial committee: AbbVie, Akeso, Agios, Amgen, Astellas, BeiGene, BioCryst, Boehringer Ingelheim, Celgene/Bristol Myers Squibb, Chiesi/Cornerstone Biopharma, Daiichi Sankyo, Dr Reddy, Epizyme, FibroGen, Glycomimetics, Genentech, Gilead, Geron, GSK, Janssen, Jasper, Karyopharm, Keros, Kura, Kyowa Kirin, Notable, Novartis, Orum, Otsuka, Pfizer, Regeneron, Rigel, Schrodinger, Seattle Genetics, Servier, Shattuck Labs, Syndax, Syros, Takeda, Treadwell, Taiho, Vincerx, Zentalis.